What are the major landmark hypertension trials and meta‑analyses?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Major Landmark Hypertension Trials and Meta-Analyses

The evolution of hypertension management has been shaped by several pivotal randomized controlled trials and meta-analyses that have fundamentally transformed our understanding of blood pressure treatment, with the most influential being the Veterans Administration trials (1967-1970), SHEP, ALLHAT, SPRINT, and the Blood Pressure Lowering Treatment Trialists' Collaboration meta-analyses.

Historical Foundation Trials

Early Treatment Evidence (1960s-1970s)

The Veterans Administration Cooperative Study Group trials established the foundational evidence for treating hypertension 1:

  • 1967 trial: Demonstrated compelling benefit in adults with DBP ≥105 mm Hg
  • 1970 trial: Extended evidence to those with DBP 90-104 mm Hg
  • These trials shifted hypertension management from DBP-focused to recognizing SBP importance, particularly in older adults

Systolic Hypertension Trials

SHEP (Systolic Hypertension in the Elderly Program) was the first trial proving benefit of treating isolated systolic hypertension in adults ≥60 years 1, 2. This fundamentally changed the misconception dating from 1926 that high SBP reflected a "strong heart" and only DBP mattered 1.

Modern Era Landmark Trials

ALLHAT (Antihypertensive and Lipid-Lowering to Treat Heart Attack Trial)

ALLHAT remains the best-designed comparison of first-step antihypertensive therapy 1, 3:

  • Demonstrated superiority of chlorthalidone (long-acting diuretic) over doxazosin (α-blocker)
  • Chlorthalidone, amlodipine, and lisinopril showed similar coronary outcomes and mortality
  • Chlorthalidone reduced heart failure more effectively, especially versus amlodipine
  • Established thiazide diuretics and calcium channel blockers as preferred first-line agents

SPRINT (Systolic Blood Pressure Intervention Trial)

SPRINT represents the most influential recent trial 1, 4, 3:

  • Demonstrated benefit of intensive therapy targeting SBP <120 mm Hg versus <140 mm Hg
  • Benefits applied across all prespecified subgroups, including those ≥75 years
  • Reduced not only cardiovascular events but also mild cognitive impairment and dementia
  • Included patients with 10-year CVD risk ≥15%, supporting risk-based treatment strategies 4
  • 17% of participants had baseline CVD, showing benefit in secondary prevention 4

HYVET (Hypertension in the Very Elderly Trial)

HYVET (2008) established benefit of BP lowering in those ≥80 years 1, 5, filling a critical evidence gap for very elderly patients.

STEP (Strategy of Blood Pressure Intervention in the Elderly)

Randomized adults aged 60-80 years to SBP target 110-130 mm Hg versus 130-150 mm Hg, with 6% having baseline CVD 4.

Critical Meta-Analyses

Blood Pressure Lowering Treatment Trialists' Collaboration

This represents the most comprehensive meta-analysis evidence base 4, 5:

  • Analysis of 344,716 participants from 48 RCTs
  • Demonstrated similar relative benefit (18% risk reduction per 5 mm Hg SBP lowering) regardless of baseline CVD status
  • Relative risk: 0.89 for those with CVD, 0.91 for those without CVD
  • Treatment provides similar relative risk reduction across all levels of predicted CVD risk, but greater absolute risk reduction at higher baseline risk 4

Baseline BP and Treatment Benefit Meta-Analysis

A 2018 meta-analysis of 74 trials (306,273 participants) stratified by baseline SBP 6:

  • Baseline SBP ≥160 mm Hg: Substantial reduction in major cardiovascular events (RR 0.78) and mortality (RR 0.93)
  • Baseline SBP 140-159 mm Hg: Moderate benefit for events (RR 0.88) and mortality (RR 0.87)
  • Baseline SBP <140 mm Hg: No association with mortality (RR 0.98) or major events (RR 0.97) in primary prevention
  • In patients with prior CHD at mean baseline SBP 138 mm Hg, treatment reduced events (RR 0.90) but not mortality

Drug Class Comparison Meta-Analyses

Head-to-head comparisons of 50 trials (247,006 patients) revealed class-specific differences 7:

  • Diuretics: Superior for heart failure prevention
  • Beta-blockers: Less effective for stroke prevention
  • Calcium antagonists: Superior for stroke and all-cause death, inferior for heart failure
  • ACE inhibitors: More effective for coronary disease, less for stroke
  • ARBs: Inferior for coronary disease prevention
  • RAS blockers: More effective for heart failure

Secondary Prevention Meta-Analysis

A 2011 meta-analysis of 25 studies (64,162 participants without hypertension but with CVD history) 8:

  • 23% stroke reduction (RR 0.77)
  • 20% MI reduction (RR 0.80)
  • 29% heart failure reduction (RR 0.71)
  • 15% composite CVD reduction (RR 0.85)
  • 17% CVD mortality reduction (RR 0.83)
  • 13% all-cause mortality reduction (RR 0.87)

Nonpharmacological Intervention Trials

TOHP (Trials of Hypertension Prevention)

Identified weight loss and sodium reduction as the two most effective behavioral interventions for preventing hypertension 1.

DASH (Dietary Approaches to Stop Hypertension)

Eight-week feeding study in 459 adults demonstrated BP-lowering efficacy of a diet high in fruits, vegetables, and low-fat dairy products 1. Subsequent trials showed sodium reduction combined with DASH diet produced the greatest BP reductions.

Key Mathematical Evidence

A 2025 analysis demonstrated near-perfect mathematical concordance between observational risk and treatment benefit 9:

  • For observed CVD risk increases of 12.5%, 25%, 50%, and 75% with BP elevations of 5,10,20, or 40 mm Hg, treatment produced corresponding risk reversals of 7%, 17-22%, 54%, and 64%
  • This mathematical precision validates the causal relationship between BP and CVD outcomes

Clinical Implications

The collective evidence from these landmark trials establishes:

  1. Treatment benefit exists across a wide range of baseline BPs, with greater absolute benefit at higher baseline risk
  2. Thiazide diuretics (especially chlorthalidone) and calcium channel blockers are preferred first-line agents for most patients
  3. Intensive BP lowering to <120 mm Hg provides additional benefit in high-risk patients
  4. Treatment benefits extend to very elderly patients (≥80 years)
  5. Risk-based treatment strategies are more efficient than BP-alone strategies for targeting therapy 4

References

Related Questions

In a 14-year-old adolescent with incidentally discovered severe hypertension (systolic 180–200 mm Hg) and no identified cause, what is the appropriate work‑up and management plan?
How should a 19-year-old male with hypertension be evaluated?
What are the 2025 ACC/AHA guideline recommendations for blood pressure targets, lipid management, heart failure therapy, post‑myocardial infarction secondary prevention, stable coronary artery disease, and atrial fibrillation anticoagulation in adults?
What are the 2025 American Heart Association (AHA) recommendations for electrical and pharmacologic cardioversion, including anticoagulation requirements, drug dosing, and post‑cardioversion management?
How should a blood pressure of 143/98 mm Hg be interpreted and managed?
What is the average 24‑hour premature atrial contraction (PAC) burden in healthy adults without known cardiac disease?
How does eating bacon affect my estimated glomerular filtration rate (eGFR)?
Can a six‑day course of methylprednisolone (corticosteroid) increase my hemoglobin A1c from 5.4% to 5.8% (approximately a 0.4% rise)?
Why is gentamicin given to newborn infants?
Two weeks after discontinuing methylprednisolone, my hemoglobin A1c is 5.8% (previously normal). Does this indicate pre‑diabetes, and how should I manage it?
Which supplements or vitamins are contraindicated for a patient taking apremilast (Otezla), losartan, hydrochlorothiazide, and golimumab?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.